LIMN

Company Overview — What Does Liminatus Pharma, Inc. Do?

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California. Liminatus Pharma, Inc. (LIMN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Chris Kim J.D., headquartered in LA PALMA, California. With a market capitalization of $7M, LIMN is one of the notable companies in the Healthcare sector.

Liminatus Pharma, Inc. (LIMN) Stock Rating — Avoid (April 2026)

As of April 2026, Liminatus Pharma, Inc. receives a Avoid rating with a composite score of 25.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.LIMN ranks #4,071 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Liminatus Pharma, Inc. ranks #713 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LIMN Stock Price and 52-Week Range

Liminatus Pharma, Inc. (LIMN) currently trades at $0.19. The stock lost $0.02 (9.2%) in the most recent trading session. The 52-week high for LIMN is $33.66, which means the stock is currently trading -99.4% from its annual peak. The 52-week low is $0.21, putting the stock -11.0% above its annual trough. Recent trading volume was 1.6M shares, reflecting moderate market activity.

Is LIMN Overvalued or Undervalued? — Valuation Analysis

Liminatus Pharma, Inc. (LIMN) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth.

At current multiples, Liminatus Pharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Liminatus Pharma, Inc. Profitability — ROE, Margins, and Quality Score

Liminatus Pharma, Inc. (LIMN) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 0.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -7961.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LIMN Debt, Balance Sheet, and Financial Health

Liminatus Pharma, Inc. has a debt-to-equity ratio of -88.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.05x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $1M. Cash and equivalents stand at $724,502.

LIMN has a beta of 0.13, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Liminatus Pharma, Inc. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Liminatus Pharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Liminatus Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.43. Net income for the quarter was $-10M. Operating income came in at $-3M.

In FY 2025, Liminatus Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.43. Net income for the quarter was $-10M. Operating income came in at $-3M.

In Q3 2025, Liminatus Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.07. Net income for the quarter was $-2M. Operating income came in at $-701,170.

In Q2 2025, Liminatus Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $0.00. Net income for the quarter was $113,287. Operating income came in at $-1M.

Over the past 5 quarters, Liminatus Pharma, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing LIMN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LIMN Dividend Yield and Income Analysis

Liminatus Pharma, Inc. (LIMN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LIMN Momentum and Technical Analysis Profile

Liminatus Pharma, Inc. (LIMN) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

LIMN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Liminatus Pharma, Inc. (LIMN) ranks #713 out of 838 stocks based on the Blank Capital composite score. This places LIMN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LIMN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LIMN vs S&P 500 (SPY) comparison to assess how Liminatus Pharma, Inc. stacks up against the broader market across all factor dimensions.

LIMN Next Earnings Date

No upcoming earnings date has been announced for Liminatus Pharma, Inc. (LIMN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LIMN? — Investment Thesis Summary

The quantitative profile for Liminatus Pharma, Inc. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 31/100) increases portfolio risk.

In summary, Liminatus Pharma, Inc. (LIMN) earns a Avoid rating with a composite score of 25.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LIMN stock.

Related Resources for LIMN Investors

Explore more research and tools: LIMN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LIMN head-to-head with peers: LIMN vs AZN, LIMN vs SLGL, LIMN vs VMD.